The tragic passing of Presley Gerber on Sunday, September 20, 2026, at a rehabilitation facility in southern California sent shockwaves through the entertainment and fashion industries. At just 27 years old, the model and media figure lost his life under circumstances that immediately triggered a multi-agency law enforcement investigation. The core of this inquiry focuses on the active prescription and administration of ketamine by a medical doctor, despite Gerber having a thoroughly documented history of substance dependency.

This devastating event brings a harsh spotlight onto the complex intersection of psychiatric medicine, addiction treatment, and physician accountability. Investigators are carefully piecing together the timeline of how a high-risk dissociative substance found its way into the hands of a vulnerable patient inside a controlled treatment environment. The unfolding situation raises urgent questions regarding prescribing ethics, medical oversight, and the safety protocols governing specialized care facilities.

The Investigation Into Presley Gerber Prescription Practices

Details of the Southern California Facility Incident

Emergency responders and local law enforcement arrived at the southern California treatment center following urgent calls reporting a suspected fatal medical emergency. Initial findings at the scene revealed a deeply troubling scenario, prompting detectives to secure medical records and interview facility personnel immediately. The rapid response underscored the gravity of the situation as authorities sought to preserve all physical and digital evidence related to his final hours.

Witness accounts from individuals inside the facility during his final hours paint a distressing picture of physical decline. Several sources noted that Gerber appeared visibly unwell and heavily under the influence prior to his passing. These testimonies direct investigators to examine whether staff members recognized these warning signs and whether appropriate medical interventions were deployed in time to prevent the tragedy.

Timeline of Medical Oversight and Physician Knowledge

Medical records seized by investigators outline a troubling timeline regarding the issuance of the ketamine prescription. Documentation indicates that the prescription was active right up until his final days at the facility. Investigators are analyzing the exact dates of the authorization, the dosage amounts, and the frequency of administration to establish a clear paper trail of medical involvement.

Close friends and associates came forward with alarming assertions, confirming that the prescribing physician possessed full awareness of Gerber’s prior addiction struggles. Many within his circle expressed intense frustration, arguing that supplying a potent dissociative drug to a recovering addict amounts to severe medical negligence. Legal experts are now evaluating whether the prescribing doctor acted independently or under the umbrella of an affiliated clinic.

Regulatory Oversight and Off-Label Ketamine Use

FDA Approval Guidelines and Therapeutic Boundaries

The United States Food and Drug Administration maintains strict guidelines regarding ketamine, approving the substance primarily as a general anesthetic for surgical procedures. The federal agency does not recognize or approve ketamine as a treatment for substance abuse, dependency issues, or chronic addiction recovery. Using the drug for these purposes falls outside standard federal safety approvals.

Medical professionals sometimes utilize ketamine off-label for psychiatric conditions such as treatment-resistant depression and severe anxiety. However, regulatory bodies emphasize that off-label use requires rigorous patient screening, constant monitoring, and absolute avoidance in individuals with active dependency records. The divergence between approved anesthetic uses and unregulated psychiatric deployment remains a central point of debate among medical ethicists.

Risks Associated With High-Risk Substances in Addiction Treatment

Prescribing dissociative drugs to patients battling active substance dependency introduces catastrophic medical dangers. Ketamine alters sensory perception and induces a trance-like state, which can easily trigger relapse or interact dangerously with other substances in the body. Clinical protocols generally dictate that addiction treatment facilities maintain strict drug-free environments to protect recovering individuals from high-risk pharmacological triggers.

Accountability standards for medical professionals operating independently or through boutique clinics face intense scrutiny in light of recent events. Regulatory watchdogs argue that loopholes in outpatient oversight allow rogue practitioners to skirt ethical boundaries. Lawmakers are facing renewed pressure to establish federal guidelines that penalize doctors who compromise patient safety for experimental or high-risk therapies.

Alternative Therapies and Experimental Addiction Treatments

Exploration of Ibogaine and Other Experimental Protocols

Before entering the southern California rehabilitation facility, Gerber reportedly explored various alternative treatments for addiction, including the psychoactive substance ibogaine. Derived from a West African shrub, ibogaine has gained attention in underground and alternative medical circles for its purported ability to interrupt severe addiction cycles and reduce withdrawal symptoms.

Research cited by the National Institutes of Health indicates that ibogaine exhibits potential anti-addictive properties in controlled testing environments. However, federal and international health agencies maintain strict limitations on its use due to severe cardiovascular risks, including fatal heart arrhythmias. The lack of mainstream medical consensus leaves desperate patients vulnerable to unregulated practitioners offering unproven cures.

Safety Profiles of Unregulated Substance Interventions

Seeking alternative or experimental care outside standard regulatory frameworks exposes vulnerable individuals to severe, unmonitored hazards. Without clinical supervision and emergency resuscitation equipment, psychedelic and dissociative interventions can quickly turn fatal. Medical experts caution that desperation often drives individuals past safe clinical boundaries into dangerous therapeutic environments.

Parallels to Prior High-Profile Cases

The Matthew Perry Precedent and Outpatient Ketamine Risks

The tragic circumstances surrounding Gerber draw immediate parallels to the 2023 death of acclaimed actor Matthew Perry. The Los Angeles County Medical Examiner determined that Perry died from the acute effects of ketamine use. Perry had been utilizing the substance under medical supervision for depression and anxiety management, exposing systemic vulnerabilities in outpatient ketamine protocols.

These high-profile incidents highlight a dangerous trend where clinical or outpatient ketamine management lacks the rigorous safeguards necessary to prevent abuse. When physicians supply potent psychoactive drugs without adequate oversight of the patient’s immediate environment, the risk of a fatal outcome multiplies exponentially.

Broader Industry Implications for Medical Supervision

Legal experts and medical watchdogs are demanding stricter enforcement and oversight on all ketamine administration practices. Calls for reform include mandatory reporting of off-label psychiatric prescriptions, enhanced tracking of controlled substances in rehabilitation centers, and harsher penalties for doctors who ignore a patient’s documented history of addiction.

Rehabilitation Facility Inquiry and Pending Toxicological Reports

Interviews With Patients and Facility Staff

Law enforcement officials continue their thorough investigation by conducting extensive interviews with facility personnel, attending physicians, and resident patients. Investigators are reviewing internal facility protocols to determine whether staff members adhered to safety standards or if negligence played a role in the tragedy. Coordination between external physicians and facility nurses remains a primary focus.

Former associates and public figures, including close friend Charlotte D’Alessio, shared public tributes expressing deep grief over the loss. The outpouring of sorrow from his peers emphasizes the profound impact of his passing on the creative community, while also amplifying demands for systemic transparency and accountability.

Awaiting Official Medical Examiner Conclusions

The official cause of death remains pending while authorities await the final toxicology report from the medical examiner. This comprehensive analysis will clarify whether the prescribed ketamine, contaminants, or other undisclosed substances were present in his system at the time of death. Until the report is finalized, the full legal and medical implications of the investigation will continue to develop.